Change from baseline fasting plasma glucose was -1.3 mmol/l in the albiglutide group and +0.4 mmol/l in the placebo group ( p < 0.0001 ) ; a significantly higher percentage of patients reached the HbA1c goals with albiglutide ( p < 0.0001 ) , and the rate of hyperglycaemia rescue up to week 52 for albiglutide was 24.4 versus 47.7 % for placebo ( p < 0.0001 ) .